HIV Infections (HIV Infection)

Subscribe to Selected New Research on HIV Infections

10776 relevant articles (555 outcomes, 1163 trials/studies) found for this Disease

Description: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).

Also Known As:

HIV Infection; Infection, HIV; HTLV III Infections; HTLV III LAV Infections; HTLV-III Infection; HTLV-III-LAV Infection; Infection, HTLV-III; Infection, HTLV-III-LAV; Infections, HIV; Infections, HTLV-III; Infections, HTLV-III-LAV; T Lymphotropic Virus Type III Infections, Human; HTLV-III Infections; HTLV-III-LAV Infections; T-Lymphotropic Virus Type III Infections, Human

Relationship Network

Disease Context: Research Results

Immune System Diseases: 1319

Immunologic Deficiency Syndromes: 70

HIV Infections: 10776

Acquired Immunodeficiency Syndrome: 23572

AIDS-Related Complex: 4848

AIDS Dementia Complex: 354

HIV Seropositivity: 278

AIDS-Associated Nephropathy: 94

HIV-Associated Lipodystrophy Syndrome: 66

HIV Wasting Syndrome: 48

HIV Enteropathy: 12

Central Nervous System AIDS Arteritis

Related Diseases

1.	Acquired Immunodeficiency Syndrome (AIDS)
2.	Infection
3.	Sexually Transmitted Diseases (Sexually Transmitted Disease)
4.	Tuberculosis
5.	Disease Progression

Experts

1.	Lazzarin, A: 8 articles (08/2008 - 01/2000)
2.	Douglas, Steven D: 7 articles (06/2006 - 11/2002)
3.	Ho, Wen-Zhe: 6 articles (06/2008 - 11/2002)
4.	Perry, Caroline M: 5 articles (01/2008 - 01/2002)
5.	Frøland, S S: 5 articles (12/2005 - 03/2000)
6.	Montaner, Julio S G: 5 articles (01/2005 - 01/2002)
7.	Hirschel, Bernard: 5 articles (06/2004 - 03/2002)
8.	Tambussi, G: 5 articles (01/2002 - 01/2000)
9.	Wang, Xu: 4 articles (06/2008 - 11/2002)
10.	Manfredi, Roberto: 4 articles (06/2008 - 01/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to HIV Infections:

1.	Zidovudine (Retrovir)FDA LinkGeneric 07/10/1996 - "CONCLUSIONS--Assuming demonstrable efficacy of short-course zidovudine prevention of perinatal HIV, a national perinatal HIV prevention program with zidovudine in most sub-Saharan African country settings would reduce the incidence of infant HIV infection and, in some settings, provide societal savings; however, substantial initial investment in such programs will be required. " 07/01/1996 - "The termination of the perinatal HIV transmission trial, ACTG 076, by the Data Safety and Monitoring Board in February 1994 because of the efficacy of zidovudine (ZDV) in substantially reducing maternal-infant HIV transmission has created a considerable need for efficacious patient education approaches and materials for women with and at risk of HIV infection. " 01/01/1991 - "Our results show that zidovudine treatment in the asymptomatic phase of HIV infection did not result in a sustained improvement in T-cell function. " 01/01/2003 - "3'-Azido-3'-deoxythymidine (AZT) is the first clinically effective drug for the treatment of human immunodeficiency virus (HIV) infection. " 02/01/1996 - "Zidovudine (ZDV, AZT) is the first clinically effective drug licensed for use in the treatment of human immunodeficiency virus (HIV) infection. " Order ALL the reference details at left...
2.	Protease Inhibitors (Protease Inhibitor)IBA 08/01/2007 - "BACKGROUND: Protease inhibitors were a major therapeutic breakthrough in the mid-1990s for the treatment of HIV infection, which resulted in improved life expectancy for patients who had failed previous therapies. " 05/12/1999 - "BACKGROUND: Combination antiretroviral therapy including protease inhibitors (combo+PI) is effective in suppressing systemic viral load in HIV infection, but its impact on HIV-associated cognitive impairment is unclear. " 03/01/2003 - "Having changed the landscape in the treatment of HIV infection, the functional efficacy of current protease inhibitors (PIs) remains limited by their pharmacokinetic and pharmacodynamic profiles. " 02/01/1999 - "The advent of improved medical therapy with multidrug HIV medicines including protease inhibitors has prolonged life expectation of patients with HIV infection. " 02/10/1996 - "Protease inhibitors show promise in HIV infection." Order ALL the reference details at left...
3.	AntigensIBA 04/01/2008 - "CONCLUSIONS: The PRISM HIV antigen-antibody combination assay demonstrated a significant reduction of the window period for diagnosis of HIV infection. " 01/01/1993 - "So the laboratory screening of blood should be improved by using more sensitive and specific antibody kits, including the use of HIV antigen testing, which have been reported to be useful in the diagnosis of patients with the early HIV infection." 06/01/1988 - " Viral antigen tests now are helpful in the diagnosis of congenital HIV infection but are costly and not widely available. " 04/01/1987 - "The assay for HIV antigen in the CSF may be of value in determining the prognosis of children with HIV infection and for evaluating the efficacy of therapeutic agents against this retrovirus." 09/01/1994 - "In an attempt to compare the protective effect of vaccination with two forms of envelope antigens, and to define immunological correlates of protection against HIV infection, chimpanzees were vaccinated with either recombinant gp160 or gp120. " Order ALL the reference details at left...
4.	AntibodiesIBA 11/01/1998 - "We propose that vaccine preparations able to trigger VH3(+) antibodies might confer a better protection against HIV infection. " 05/01/1996 - "Results from vaccine trials in animal models suggest that these antibodies may contribute to protection against human immunodeficiency virus (HIV) infection. " 05/01/2003 - "Case report: an 83-year-old heterosexual man with malaise tested positive for HIV infection antibodies and has responded well to triple antiretroviral therapy. " 03/01/1999 - "Protection against SIV or HIV infection requires specific antibodies and T-cell immune responses. " 01/01/2009 - "Overall, our study indicates that more than one pathway leads to the development of broad cross-reactive neutralizing antibodies during HIV infection and that the virus continuously escapes their action." Order ALL the reference details at left...
5.	Biological Markers (Surrogate Marker)IBA 05/01/2003 - "Despite some limitations (distribution assumption, ignorance of missingness process), such a model appeared to be very useful to correctly describe the current evolution of important biomarkers in HIV infection." 09/15/1997 - "Twenty-four weeks later, the mean values of all measures of viral burden and surrogate markers of HIV infection were either unchanged or improved, but none of the changes was statistically significant. " 01/01/1995 - "The CD4+ cell count is a surrogate marker used for evaluating the efficacy of therapies for HIV infection and for estimating the prognosis of patients with HIV infection. " 01/01/2007 - "A study was conducted among patients attending a public health centre in Nairobi, Kenya in order to (a) verify the prevalence of HIV, (b) identify clinical risk factors associated with HIV and (c) determine clinical markers for clinical screening of HIV infection at the health centre level. " 01/01/2004 - "viral load) have become established surrogate markers for predicting treatment and disease outcome in HIV infection, and are instrumental for the evaluation of new antiretroviral drugs in clinical trials. " Order ALL the reference details at left...
6.	Thalidomide (Thalomid)FDA Link 02/01/1995 - "Several previous reports have suggested that thalidomide therapy is beneficial for patients with aphthous ulceration related to human immunodeficiency virus (HIV) infection. " 05/22/1997 - "CONCLUSIONS: Thalidomide is an effective treatment for aphthous ulceration of the mouth and oropharynx in patients with HIV infection." 09/11/1993 - "[Efficacy of thalidomide against esophageal ulceration in HIV infection]" 04/21/1995 - "Thalidomide is in trials for the treatment of primary HIV infection at five sites. " 10/01/2001 - "Use of thalidomide in HIV infection." Order ALL the reference details at left...
7.	Anti-Retroviral Agents (Antiretroviral Agents)IBA 01/15/2009 - "The recent availability of new antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection has increased treatment options and has improved the durability, tolerability, and long-term efficacy of antiretroviral therapy, even among patients with extensive treatment experience and high levels of drug resistance. " 09/01/2003 - "OBJECTIVE: Pharmacokinetic data obtained from children who have human immunodeficiency virus (HIV) infection are essential for the safe and effective use of antiretroviral agents in pediatric populations. " 12/01/1994 - "Because the efficacy of currently approved antiretroviral agents used as prolonged monotherapy is limited, there is an urgent need for alternative agents for the treatment of HIV infection. " 07/01/2009 - "The improved efficacy and safety of antiretroviral agents have fundamentally changed the face of HIV infection. " 10/01/2007 - "Design of new gender-sensitive clinical trials with both prolonged follow-up and sample size representative of the current HIV prevalence among women are strongly needed to detect the likely sex differences of antiretroviral agents during HIV infection." Order ALL the reference details at left...
8.	VaccinesIBA 09/01/1998 - "An understanding of the different immune mechanisms capable of inhibiting HIV infection may be of benefit in the eventual design of vaccines effective against HIV-1 variants. " 07/01/2006 - "RECENT FINDINGS: Clinical trial design depends, in large part, on whether vaccines are expected to provide protection against HIV infection or mitigation such as slowing progression of disease or reducing transmissibility. " 04/01/1989 - "Because HIV infection is associated with immunologic abnormalities, concerns have been expressed about the safety and efficacy of vaccination of infected children with live virus vaccines. " 01/01/2007 - "PURPOSE OF REVIEW: To outline the rationale for testing therapeutic vaccines in HIV infection and to discuss the ways in which the antiviral activities of these vaccination trials can be evaluated. " 01/01/2007 - "Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption." Order ALL the reference details at left...
9.	Didanosine (Videx)FDA LinkGeneric 12/01/1996 - "In conclusion, didanosine monotherapy is an effective treatment of HIV infection. " 02/01/1997 - "Italian multicentre study of didanosine compassionate use in advanced HIV infection. " 05/01/1995 - "Starting in 1988, 72 patients with advanced human immunodeficiency virus (HIV) infection were enrolled in a phase I study of didanosine at the National Cancer Institute. " 08/01/2004 - "A 63-year-old man with human immunodeficiency virus (HIV) infection tolerated several didanosine-containing antiretroviral regimens. " 12/01/2002 - "Didanosine remains a cornerstone nucleoside analogue for the treatment of HIV infection. " Order ALL the reference details at left...
10.	Lamivudine (3TC)FDA Link 03/01/1996 - "The NIAID Pediatric ACTG also supports other clinical trials for children with HIV infection, including a study comparing the efficacy of AZT plus 3TC to AZT plus ddI and to ddI alone. " 11/01/1996 - "OBJECTIVE: To assess the efficacy of lamivudine in inhibiting HBV replication during a 12-month period in patients with both HBV and HIV infection. " 02/15/2008 - "CONCLUSIONS: Our study found that poor adherence and 3TC resistance acquired after the intervention to prevent mother-to-child transmission of HIV infection were associated with virologic failure in women who initiated antiretroviral treatment." 10/01/1998 - "STUDY DESIGN: Children with symptomatic human immunodeficiency virus (HIV) infection, 6 weeks through 15 years of age, were stratified according to age and randomly assigned to receive ddI, ZDV/3TC, or ZDV/ddI. " 07/01/1995 - "A list of current and upcoming trials of 3TC in people with HIV infection is provided." Order ALL the reference details at left...

Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART) 05/01/2004 - "STUDY OBJECTIVES: The use of highly active antiretroviral therapy (HAART) has dramatically improved morbidity and mortality in patients with HIV infection. " 06/01/2007 - "Highly active antiretroviral treatment (HAART) has revolutionized the HIV treatment, leading to a significantly decreased morbidity, prolonged survival, and an overall better outcome of HIV infection. " 05/01/2004 - "The prognosis of HIV infection has improved dramatically since the introduction of highly active antiretroviral therapy (HAART). " 01/01/2004 - "The introduction of highly active anti-retroviral therapy (HAART) for Human Immunodeficiency Virus (HIV) infection has significantly improved the life expectancy of HIV positive patients. " 01/01/2004 - "Highly active antiretroviral therapy (HAART) has dramatically reduced mortality from HIV infection, transforming it in many cases to a chronic condition. " Order ALL the reference details at left...
2.	Condoms (Condom) 10/01/2006 - "RESULTS: If all components of the intervention reach target coverage (that is, PPT, STI treatment and condom use), the intervention is expected to prevent 22-35% of all new HIV infections in FSW and in the total population over 5 years in a low transmission setting like Mysore, and to be half as effective in high transmission settings such as Bagalkot. " 01/01/2003 - "Mean age was 41 years, 82.5% were male and 75.5% benefited from high school education; 75.75% had a good level of knowledge on HIV infection, 58% CI [51-65] stated having changed their sexual behavior into abstinence, fidelity to their partner (52.5%) and use of condom (46.5%). " 09/01/1997 - "While 29% perceived recapping needles as involving no risk, activities involving casual contact with patients and condom use for protection against HIV infection were associated with a high perceived risk of HIV transmission, particularly among nurses. " 07/01/1995 - "A targeted distribution of condoms to populations with a high demonstrated risk may be more effective in preventing new HIV infection." 04/03/1993 - " More health education is being carried out in Egypt than in any other Arab country except Lebanon, and the availability of condoms for family planning purposes helps in the protection against HIV infection." Order ALL the reference details at left...
3.	Drug Therapy (Chemotherapy) 01/01/1996 - "However, there may be a subpopulation of HIV-infected patients with Burkitt's-type NHL and well preserved immune status who may benefit from high-dose chemotherapy programs that are effective for BL patients without HIV infection." 04/25/2005 - "Drug therapy of HIV infection has become more effective in the last years. " 09/01/1998 - "Improved management of the underlying HIV infection, more effective infusional chemotherapy regimens, moderately effective second line regimens, and new investigational approaches all offer promising hope that improvements will soon be seen for the treatment of HIV-related systemic NHL. " 02/01/1992 - "This will permit a polychemotherapeutic approach against HIV infection that, as in the case of anticancer chemotherapy, has conceivably better chances to be effective in patients with HIV-related disease." 10/01/2000 - "CONCLUSIONS: Current USPHS PEP recommendations are marginally cost effective compared with monotherapy, but the additional efficacy of triple drug therapy for all risk categories is rewarded by only a small reduction in HIV infections at great expense. " Order ALL the reference details at left...
4.	Male Circumcision (Circumcision) 01/01/2006 - "BACKGROUND: A landmark randomised trial of male circumcision (MC) in Orange Farm, South Africa recently showed a large and significant reduction in risk of HIV infection, reporting MC effectiveness of 61% (95% CI: 34%-77%). " 11/01/2005 - "CONCLUSION: Male circumcision provides a degree of protection against acquiring HIV infection, equivalent to what a vaccine of high efficacy would have achieved. " 03/01/2007 - "Male circumcision has been demonstrated effective in reducing risk for HIV infection in three separate trials from South Africa, Kenya, and Uganda. " 02/01/2008 - "In Slovenia, where HIV prevalence is <1/1000 citizens and HIV infection is concentrated in men who have sex with men, promoting male circumcision in the general population may not be effective for HIV prevention purposes." 02/01/2007 - "RECENT FINDINGS: The report from the randomized clinical trial of male circumcision in South Africa demonstrating a 60% protective effect in preventing HIV acquisition provided the first clinical trial evidence of efficacy of male circumcision in protecting men against HIV infection. " Order ALL the reference details at left...
5.	Art Therapy 10/01/2005 - "BACKGROUND: Survival in HIV infection has improved dramatically in the last decade due to antiretroviral therapy (ART). " 09/01/2008 - "PURPOSE: Combination antiretroviral therapy (ART) has proven to be effective in treating human immunodeficiency virus (HIV) infection. " 01/01/2005 - "OBJECTIVES: The objective of this systematic review was to assess the effects of structured treatment interruptions (STI) of antiretroviral therapy (ART) in the management of chronic suppressed HIV infection, using all available high-quality studies. " 04/01/2009 - "Antiretroviral therapy (ART) inhibits HIV replication, allowing recovery of CD4+ T cell numbers and the restoration of immune function; its introduction has led to improved outcomes for individuals with HIV infection. " 03/01/2007 - "We review relevant literature on mortality in children born to HIV infected mothers; morbidity and mortality associated with paediatric HIV infections; eligibility to and efficacy of antiretroviral therapy (ART). " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on HIV Infections

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 555 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>